CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y **ao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Acute myeloid leukemia: current progress and future directions
H Kantarjian, T Kadia, C DiNardo, N Daver… - Blood cancer …, 2021 - nature.com
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
HLA-independent T cell receptors for targeting tumors with low antigen density
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune
responses. Tumor escape associated with low target antigen expression is emerging as one …
responses. Tumor escape associated with low target antigen expression is emerging as one …
[HTML][HTML] Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
Chimeric antigen receptor (CAR) T cell therapy is effective in lymphoid malignancies, but
there has been limited data in myeloid cancers. Here, we start with a CD27-based CAR to …
there has been limited data in myeloid cancers. Here, we start with a CD27-based CAR to …
The CD70-CD27 axis in oncology: the new kids on the block
T Flieswasser, A Van den Eynde… - Journal of experimental …, 2022 - Springer
The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in
many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within …
many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within …
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
The prognosis of patients with acute myeloid leukemia (AML) remains dismal, highlighting
the need for novel innovative treatment strategies. The application of chimeric antigen …
the need for novel innovative treatment strategies. The application of chimeric antigen …
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …
Analysis of clonogenic growth in vitro
N Brix, D Samaga, C Belka, H Zitzelsberger… - Nature protocols, 2021 - nature.com
The clonogenic assay measures the capacity of single cells to form colonies in vitro. It is
widely used to identify and quantify self-renewing mammalian cells derived from in vitro …
widely used to identify and quantify self-renewing mammalian cells derived from in vitro …
Updates on targeted therapies for acute myeloid leukaemia
S Kayser, MJ Levis - British journal of haematology, 2022 - Wiley Online Library
In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
leukaemia (AML) has led to remarkable advances in our understanding of the disease …